PROGNOSTIC FACTORS FOR OUTCOMES IN ALLOGENEIC TRANSPLANTATION FOR ADVANCED PHASES OF CHRONIC MYELOID LEUKEMIA IN THE IMATINIB ERA: A CIBMTR ANALYSIS

Allogeneic hematopoietic stem cell transplantation (HSCT) is curative treatment, albeit in a minority of patients with accelerated (AP) or blast phase (BP) chronic myeloid leukemia (CML). Imatinib (IM) has transient but significant activity in advanced phases of CML, which may permit early allograft...

Descripción completa

Detalles Bibliográficos
Autores principales: Khoury, Hanna J, Kukreja, Manisha, Goldman, John M., Wang, Tao, Halter, Jorg, Arora, Mukta, Gupta, Vikas, Rizzieri, David A., George, Biju, Keating, Armand, Gale, Robert Peter, Marks, David I., McCarthy, Philip L., Woolfrey, Ann, Szer, Jeffrey, Giralt, Sergio A., Maziarz, Richard T., Cortes, Jorge, Horowitz, Mary M., Lee, Stephanie J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896981/
https://www.ncbi.nlm.nih.gov/pubmed/21986636
http://dx.doi.org/10.1038/bmt.2011.194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896981/
https://www.ncbi.nlm.nih.gov/pubmed/21986636
http://dx.doi.org/10.1038/bmt.2011.194

Ejemplares similares